Study of TYZEKA in subjects of Black/African American or Hispanic/Latino origin with compensated chronic hepatitis B virus infection.

The purpose of this study is to estimate the proportion of patients who achieve non-detectable HBV DNA in Black/Caribbean/African Americans and Hispanic/Latinos with compensated chronic hepatitis B during 24 weeks of treatment with telbivudine.

You may be eligible to participate in this study if you:

• Have documented compensated chronic Hepatitis B
• Are Black Caribbean, African American, and or Hispanics/Latino

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.